Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | GLS | O94925 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132701 | 0.94 | CYP17A1 (0.76) | CYP17A1MAPK14PPARGPPARAGLS | |
| SCHEMBL7042995 | 0.91 | DRD2 (0.59) | CYP17A1PPARGPPARAGLSDRD2 | |
| SCHEMBL1854209 | 0.88 | ATM (0.56) | CYP17A1PPARGPPARAGLSDRD2 | |
| SCHEMBL14379115 | 0.88 | CYP17A1 (0.68) | CYP17A1MAPK14PPARGPPARADRD2 | |
| SCHEMBL31557899 | 0.87 | CYP17A1 (0.57) | CYP17A1MAPK14PPARGPPARAGLS | |
| SCHEMBL31557895 | 0.87 | CYP17A1 (0.57) | CYP17A1MAPK14PPARGPPARAGLS | |
| SCHEMBL134932 | 0.86 | CYP17A1 (0.67) | CYP17A1MAPK14PPARGPPARADRD2 | |
| SCHEMBL7722182 | 0.86 | CYP17A1 (0.53) | CYP17A1PPARGPPARAGLSNAMPT | |
| SCHEMBL29260233 | 0.85 | CYP17A1 (0.92) | CYP17A1MAPK14NAMPTRAB9ASMN1; SMN2 | |
| SCHEMBL7043026 | 0.85 | POLB (0.62) | CYP17A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102482221-B | bicyclic and tricyclic compounds as KATII inhibitors | PFIZER INC. (US) | 2014-10-22 | — | — | CN | disclosed |
| CN-102482221-A | Bicyclic and tricyclic compounds as KATII inhibitors | PFIZER | 2012-05-30 | — | — | CN | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | CYP17A1 2058/4885MAPK14 1951/4885PPARG 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.